Funding, Consortia & Accreditation

Funding

VHIO can and will only deliver on its goal of accelerating the pace in advancing personalized and targeted therapies against cancer thanks to the public funding it receives as well as the generous support from institutional supporters, private institutions, companies, associations, societies, and individual donors. As a direct reflection of VHIO's research of excellence, VHIO also continues to secure essential funding through several International and National Competitive Grants. Regarding the latter, we would like to also recognize the Asociación Española Contra el Cáncer (AECC) for its longstanding support of several VHIO groups and researchers.

Only with such continued support will the clock continue to tick in our favor - against cancer. VHIO would therefore like to express its immense gratitude to its following supporters, funding entities and agencies:


Institutional Supporters

logo
logo
logo
logo
logo

Public funding

International

logo
logo
logo
logo
logo
logo

National

logo
logo
logo
logo
logo
logo

Private funding

logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo

Consortia



Cancer Core Europe (CCE) is a unique partnership aimed at addressing the cancer care - cancer research continuum challenge. Launched in 2014, this working consortium represents a critical mass of activity for the successful integration of all cancer care information, clinical research and outcome research, led by its founding partners and European comprehensive cancer centers of excellence: the Gustave Roussy Cancer Campus Grand Paris (Villejuif, France), Cambridge Cancer Centre (Cambridge, UK), Karolinska Institute (Stockholm, Sweden), Netherlands Cancer Institute – NKI (Amsterdam, The Netherlands), National Center for Tumor Diseases – DKFZ-NCT (Heidelberg, Germany), VHIO, as well as The National Cancer Institute of Milan (Italy). CEE promotes the pooling and exchange of expertise, research findings, common platforms and processes, and empowers researchers and clinicians to rapidly exploit this trove of biological insights and clinical data for the benefit of patients.
www.cancercoreeurope.eu
Supported by EU’s Horizon 2020 Framework Programme, 2020 celebrated the launch of Cancer Core Europe Consortium-Building Data Rich Clinical Trials (CCE-DART) Consortium – also listed here under New consortia – officially launched in 2020. Coordinated by VHIO, this innovative project will harness and incorporate powerful cutting-edge technologies, methods and platforms, to spur the design, development, and ringing in of a new generation of data rich, dynamic studies in oncology.

This project has received funding from the European Union’s Horizon 2020 framework programme research under grant agreement No: 965397.



Announced at the beginning of 2019, the OPTIMISTICC Cancer Grand Challenge – Opportunity to Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer- is a 5-year consortium funded by Cancer Research UK’s Grand Challenge, led by researchers at the Dana-Farber Cancer Institute-Harvard Medical School, and Harvard T.H. Chan School of Public Health (USA). Aimed at better understanding the difference between a healthy microbiome and a microbiome associated with the development of colorectal cancer, the co-investigators from the US, Canada, the UK, Netherlands, and Spain, are seeking to identify ways to manipulate this collection of microorganisms to better prevent and treat cancer.
It is thanks to the Grand Challenge Funding that the project partners, including VHIO, are able to pool the necessary expertise in order to establish how the microbiome influences a cancer’s response to treatment, develop new treatments that alter the microbiome, and decipher how an individual’s external environment may affect their microbiome. www.optimisticc.org



COLOSSUS–Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions, is a multi-center European Commission Horizon 2020-supported project powered by 14 leading clinical investigators and researchers spanning 8 European countries, with expertise in cancer immunology, systems biology, computational modelling, bioinformatics, omics analysis, clinical oncology/pathology, preclinical research, medical imaging, clinical trials, health economics and patient management. This 5-year undertaking aims at better classifying and treating metastatic colorectal cancer (mCRC). Focused on microsatellite stable RAS mutant (MSS RAS mt) disease–a genetically identified type of CRC with very few therapeutic options available once patients develop resistance to existing chemotherapies, the COLOSSUS team strives to both expand and refine the classification of this particular subset of colorectal cancer. www.colossusproject.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754923.



EUCanCAN – the European-Canadian Cancer Network, led by the Barcelona Supercomputing Center (Spain), comprises a total of 18 partners from 5 different countries to pursue the homogeneous analysis, management and exchange of genomic-driven oncology data to advance precision medicine in cancer.
Jointly funded by the European Union’s Horizon 2020 research and innovation programme and the Canadian Institutes of Health, this project strives to provide a functional platform for federated genome analysis systems towards efficiently analyzing, managing, sharing and reusing mass genomic data at the global level. The participating reference nodes seek to process, store and share between 30-35 thousand patient samples across various tumor types.
This consortium also promises to drive discovery into robust and clinically-relevant patterns of genomic variation in cancer, including predictive biomarkers. www.eucancan.com

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825835.



The EuroPDX Consortium–Translating Knowledge in Oncology, launched in 2013 to create a network of clinically relevant models of human cancer, and in particular patient-derived xenograft (PDX) models. Connecting 18 cancer centers across 13 countries that are developing PDX cancer models, this initiative promotes the sharing and exchange of findings on promising therapeutics as well as leads multicenter preclinical studies.
EuroPDX strives to reduce the duplication of efforts in oncology drug development and ultimately improve the quality of life and overall survival of cancer patients.
Supported by the European Union’s Horizon 2020 research and innovation programme and launched in 2018, EDIReX – EuroPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts, is led by the EuroPDX Consortium counting on the research excellence of 19 entities -including VHIO- spanning 13 European countries. The main aims of this project are to facilitate data exchange among academic and industrial preclinical and translational cancer professionals and, to spur and consolidate scientific collaborations in PDX research across Europe. www.europdx.eu

The EDIReX project has received funding from the European Union’s Horizon 2020 research and innovation programme, grant agreement no. #731105.




Immune-Image is a 22 stakeholder-strong consortium incorporating public and private partners across 9 countries, including VHIO and the Vall d’Hebron Institute of Research (VHIR) from Spain. Powered by the Innovative Medicines Initiative Joint Undertaking (IMI 2 JU), this initiative is led by Roche and coordinated by the Amsterdam University Medical Center (VUmC), The Netherlands. Set to run for an initial duration of five years, this project is entitled Specific imaging of immune cell dynamics using novel tracer strategies, and seeks to develop a novel non-invasive imaging strategy for assessing immune cell activation and dynamics in oncology and inflammatory disease.
Main deliverables include developing clinically validated radio-and optical immunotracers for the monitoring and measurement of immune cell presence, activation status and trafficking, and designing and implementing a ready-to-use sustainable molecular imaging platform, incorporating standardized protocols, best practices, quantitative image analyses, immune-based tracking design and development.
www.immune-image.eu



Initiated in 2016, INTRACOLOR (Evolution of resistant clones to novel target-directed drugs in colorectal tumors: a genetic and epigenetic study of intratumoural heterogeneity dynamics), is supported by EU Horizon 2020 funding and led by VHIO. Running in parallel with MoTriColor’s clinical trials, it incorporates 6 of MoTriColor’s members to test novel targeted therapies for mCRC, each matched to distinctive gene expression signatures.
Representing a comprehensive framework for translational research, emerging molecular data is prospectively integrated in preclinical models and proof-of-concept clinical trials in mCRC. This project is carried out in collaboration with SPECTAcolor–Screening Platform for Efficient Clinical Trials Access in Colorectal Cancer, which is an initiative of the EORTC, supported by Alliance Boots.
www.motricolor.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.



Funded by the European Union’s Horizon 2020 research and innovation programme, the CELAC and European Consortium for a Personalized Medicine Approach to Gastric Cancer (LEGACy) is a 4-year project spearhead by INCLIVA Health Research Institute (Spain), in partnership with 10 other members across 9 different countries including VHIO.
Focused on advancing personalized medicine against gastric cancer, this project aims to improve diagnosis and treatment by using data obtained through extensive research in four EU countries and four countries within the Community of Latin American and Caribbean (CELAC). States outcomes by applying personalized medicine at the three levels of prevention. This consortium will seek to implement a personalized medicine strategy at the first level of prevention, improve early gastric cancer detection at the second level of prevention, and improve treatment through the identification of high-risk populations.
www.legacy-h2020.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825832.



MESI-STRAT combines the expertise of 14 partners from 6 European countries to establish the interplay of breast cancer metabolism and oncogenic signaling (Metabolic Signaling) by systems medicine approaches. Aimed at developing new models for knowledge-based STRATification of patients into subgroups with different endocrine therapy resistance mechanisms, this pan-European 57-month project, supported by the European Union’s Horizon 2020 research and innovation programme, represents an important forward step towards improving outcomes for these patients.
The team pioneers breast cancer metabolism as a novel approach for the stratification of patients, tracking of resistance and better guiding clinical decision-making throughout the course of endocrine therapy. Through the development of new computational models in combination with network analyses, pharmacogenomics and integrated multi-omics data, MESI-STRAT will play a decisive role in better deciphering the metabolic and signaling networks that drive resistance to endocrine-based therapies.
www.mesi-strat.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754688.



Spurred by Horizon 2020’s European Union funding for Research and Innovation funding, MoTriColor (Molecularly guided Trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of Colorectal cancer), led by VHIO, is powered by 8 clinical research centers of excellence, spanning Spain, Italy, The Netherlands and Belgium, as well as a European organization in cancer research and a diagnostic/prognostic SME.
Dedicated to conducting multi-center early phase clinical trials to establish the anti-tumor activity of novel experimental therapies for patients with metastatic or advanced colorectal cancer, patients are stratified based on their gene expression profiles according to recently established predictive signatures.
This pioneering approach aims at identifying sensitivity of individual patients to the proposed experimental therapies towards ultimately developing more precise anti-cancer therapies for these patients.
www.motricolor.eu www.motricolor.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 635342.



Funded through a grant received from the European Union’s Horizon 2020 research and innovation programme, the NoCanTher–Nanomedicine upscaling for early clinical phases of multimodal cancer therapy is a multi-center–Consortium is led by IMDEA Nanoscience and represents an important forward step in utilizing nanoparticles than can better target and more precisely combat cancer cells.
It builds on the preclinical successes reported by the former FP7-funded MultiFun Consortium that evidenced the efficacy of a multi-modal therapeutic approach based on functionalized magnetic nanoparticles and magnetic hyperthermia for the intra-tumoral treatment of breast and pancreatic tumors.
Connecting 11 leading European research centers, including industry partners, NoCanTher assesses this nano-based apprach and provide preliminary data on its efficacy in humans and aim to translate these preclinical findings into early clinical development for the treatment of pancreatic cancer.
www.nocanther-project.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 685795.



The PhD PI3K biology in health & disease Network incorporates 10 academic, clinical and industrial partners with renowned expertise in research focused on PI3K signaling. Leading a unique training network, this collaboration connects complementary expertise and brings additional value, novel tools and leadership of excellence in order to train talented early stage researchers and suitably equip them for leading roles in cancer science and drug discovery in European industry and academia.
This research training program not only represents unparalleled educational opportunity for these young scientists, but also aims to increase the international competitiveness of European research in PI3K discovery and drug development.
www.pi3k-phdproject.eu



Incorporating a network of 27 research entities spanning 10 countries, SPECTAcolor - Screening Platform for Efficient Clinical Trials Access in Colorectal cancer, is an initiative within the framework of the research program of the EORTC, supported by Alliance Boots.
Launched in 2013, this is the first prospective fully annotated tumor samples Biobank and Biomarker analysis platform for genetic profiling of patients suffering from advanced colorectal cancer.
https://www.eortc.org/blog/category/spectacolor



RADprecise - Personalized radiotherapy: Incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicity, is supported by funding received through ERAPerMed’s co-funded Joint Translational Call 2018 and was founded in 2019 by 7 leading organizations from Spain, Italy, Germany and France. This 3-year project will render radiotherapy more precise by incorporating data from finely tuned predictive models to pre-identify toxicity based on insights from multiple biomarkers of radiosensitivity in individual patients.
Led by colleagues at the German Cancer Research Center (DKFZ), Germany, project partners will apply findings at the clinical level by integrating a treatment planning system. Using parametric models and machine learning, clinical investigators from academia and health research, in collaboration with small and medium enterprises as well as patient advocates, will apply new biological data as well as readily available genomic information to develop models that can more precisely envisage adverse effects from radiotherapy to be validated in independent samples.
www.erapermed.eu

This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 779282



The Spanish Association against Cancer (AECC), and the Institute of Health Carlos III (ISCIII) through the ERA-NET: Aligning national/regional translational cancer research activities awarded VHIO with two TRANSCAN-2 projects funded by the EU's Horizon 2020 framework program in 2017.
Supported through the TRANSCAN Joint Translational Call on Minimally and non-invasive methods for early detection and/or progression of cancer, the first will establish non-invasive prognostic markers for resected early-stage non-small cell lung cancer (NSCLC) by assessing the role of circulating and exosomal miRNAs and free circulating DNA (fcDNA); as well as characterize blood-based tumor-educate platelets (TEPs) for the evaluation of patients treated with immune checkpoint inhibitors using novel sequencing technologies.
The second project will focus on the early detection of relapse in advanced colon cancer patients by longitudinally following a personalized molecular signature by liquid biopsy. This proof-of-concept, prospective, multi-center study will primarily seek to evaluate the clinical feasibility of tracking tumor progression by dynamically detecting a molecular and personalized signature from a blood test.
www.transcanfp7.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.



Announced in 2018, one of the U.S. Department of Defense’s (DoD) Innovative Minds in Prostate Cancer (IMPaCT) Awards funds a three-year collaborative partnership to advance precision medicine against metastatic prostate cancer (mPC). This coalition counts on the multidisciplinary expertise of investigators at VHIO, the Spanish National Cancer Research Centre–CNIO (Madrid, Spain), and the University of Washington (USA).
Aimed at more precisely gauging response in patients to standard therapies, the team seeks to develop new, more effective and tailored treatment strategies, as well as design a clinical trial to assess the performance of a DNA damaging platinum chemotherapy, carboplatin, that is already used to treat other tumor types including ovarian and breast cancer.
https://cdmrp.army.mil/pcrp



WIN - Worldwide Innovative Networking in personalized cancer medicine, initiated by the Institut Gustave Roussy (France) and The University of Texas, MD Anderson Cancer Center (USA) is a non-profit, non-governmental organization incorporating 39 leading organizations representing all stakeholders in personalized cancer medicine covering 21 countries and 4 continents, united by their vision to deliver on the promise of effective, personalized cancer medicine to patients worldwide.
Under the tagline WINning together, WIN was formed on the premise that members can accomplish more together than each organization can achieve working alone. Aimed at improving cancer patients’ survival and quality of life, WIN members also collaboratively design and carry out global studies designed to achieve breakthroughs for cancer patients across the globe.
www.winconsortium.org



New Consortia – officially launched in 2020


The EU-funded Cancer Core Europe Consortium-Building Data Rich Clinical Trials (CCE-DART), coordinated by VHIO), is carried out in collaboration with other leading experts from within Cancer Core Europe Consortium. By harnessing and incorporating powerful cutting-edge technologies, methods and platforms, CCE-DART investigators will design and develop a new generation of data rich, dynamic studies in oncology.
Building on the CCE-developed Basket of Baskets (BoB) investigator-initiated and adaptive trial which launched in 2018, CCE-DART will further enhance BoB’s harmonized, molecular multi-tier profiling platform to more precisely match patients to novel anti-cancer medicines based on the genetic specificities of their individual tumors. In parallel, the researchers will continue to develop multiple treatments in genomically-selected populations.
www.cancercoreeurope.eu

This project has received funding from the European Union’s Horizon 2020 framework programme research under grant agreement No: 965397.



The main objective of the EU-supported EURAMED rocc-n-roll project: EURopeAn MEDical application and Radiation prOteCtion Concept: strategic research agenda aNd ROadmap interLinking to heaLth and digitisation aspects, is to generate a European consensus on research needs and priorities in medical radiation applications and corresponding radiation protection to optimize the use of ionizing radiation in medicine.
Led by coordinating partner, the European Institute for Biomedical Imaging Research, Vienna (Austria), this pan-European consortium connects a total of 29 research centers, including VHIO. Taking the lead on radiation application in oncological diseases, VHIO will work with other experts in other settings including neurovascular as well as cardiovascular diseases, and explore relevant clinical scenarios, as well as provide patients’ perspectives.
Specifically, VHIO researchers will analyze the needs of research in radiation application and corresponding radiation protection in oncology by identifying gaps and opportunities. Compile an overview of clinical situations that require the application of ionizing radiation in diagnosis and treatment, provide an outlook on envisaged future applications and trends in the oncology field.
www.cordis.europa.eu/project/id/899995

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No: 899995.



Coordinated by the Josep Carreras Leukemia Research Institute, Barcelona (Spain), the EU-funded Interreg POCTEFA PROTEOblood Consortium is co-funded by the European Regional Development Fund/European Social Fund, and aims to optimize, share and exploit latest technologies for the study of protein homeostasis in two prevalent subtypes of leukaemia and lymphoma: acute myeloid leukemia (AML) and diffuse large b-cell lymphoma (CLBCL) in the POCTEFA region (Spain-France-Andorra).
Comprised of six other partners - CIC bioGUNE, IQS, CNRS, INSERM, Anaxomics Biotech, and VHIO, the investigators will use modelling collections from patient-derived studies to recreate the tumor microenvironment ex vivo, and apply innovative proteomic approaches associated with system biology analysis and small molecule design, to facilitate the complete characterization of proteopathies and development of more effective therapies that will then be validated through xenoinjerts.
www.poctefa.eu/ayudas-de-estado-y-minimis The project has been co-financed by:

The European Regional Development Fund (ERDF) through the Interreg V-A Spain-France-Andorra Programme (POCTEFA 2014-2020) – Ref: EFA360/19.

European Regional Development Fund/European Social Fund.



The ERA-PerMed-supported RAD51predict Consortium, is coordinated by VHIO and centers on patient stratification based on DNA repair functionality for precision cancer medicine. Consisting of five partners: the University Clinic of Giessen and Marburg (Germany), Institut Gustave Roussy (IGR)-INSERM U981, Villejuif (France), German Breast Group Forschungs GmbH, Neu-Isenburg (Germany), Université Laval (CHUQ), Quebec (Canada), and VHIO, along with six other collaborators, will further investigate the RAD51 in vitro diagnostic test to predict those patients who would be most likely to benefit from therapy with PARP inhibitors (PARPi).
Aimed at enabling the more precise and faster identification of patients with breast and this test has been developed to better guide the stratification of patients to clinical trials to evaluate the efficacy of PARPi across additional tumor types including prostate and endometrial cancers.
www.erapermed.isciii.es




Other collaborations:


The AstraZeneca/MedImmune –VHIO Alliance drives advancements at the preclinical, clinical and translational research levels across AstraZeneca's oncology portfolio. Combining VHIO's strengths in promoting cancer discovery through the integration of translational science and clinical research with AstraZeneca's promising early stage oncology pipeline, the alliance focuses on areas including DNA damage repair, drug resistance, new drug combinations and molecular profiles for patient selection.
In 2020, AstraZeneca/Medimmune announced its Partner of Choice Network, comprising nine of the world’s most renowned research centers and institutes in oncology to accelerate research against some of the most difficult-to-treat cancers. Selected partners of choice are the Cambridge Cancer Center (UK), Institut Gustave Roussy (France), Johns Hopkins University (USA), Memorial Sloan Kettering Cancer Center (USA), Oregon Health and Science University/Knight Cancer Institute (USA), Peter MacCallum Cancer Center (Australia) Princess Margaret Cancer Center (Canada), University of Navarra (Spain), and VHIO.
This network serves a forum for data sharing and cancer discovery in real-time. Scientific insights and findings generated through clinical studies are exchanged among partner institutions for the development and implementation as best practices in oncology. AstraZeneca will support selected clinical and non-clinical research proposals from the partners’ investigators to expedite novel scientific research and innovative clinical trial design aimed at developing new strategies in precision medicine against cancer.
www.astrazeneca.com



The SCITRON Consorcio público-privado de Investigación Científica y Translacional en Oncología (Consortium for Scientific Translational Research in Oncology) is a scientific program established in collaboration with Novartis in 2017 as a new model of R&D collaboration. This initiative connects expertise from Novartis and VHIO in applied and translational research to increase the impact of basic research in clinical practice.
The specific areas of interest include the development of a technology platform that analyses tumor clonal evolution and resistance mechanisms to targeted immunotherapy.
www.novartis.com



Launched by Roche in 2016, the imCORE - immunotherapy Centres of Research Excellence Network - a 27 partner-strong network aims to advance discovery in cancer immunotherapy, connect internationally renowned scientific and clinical experts in immune-based therapeutic strategies in oncology, and collaborate together to assess and advance the most promising novel treatment approaches.
Working in collaboration with scientists from Roche and Genentech, researchers and physician-scientists in cancer immunotherapy from across the globe aim to drive the application and extension of immune-based strategies to more tumor types, as well as advance research into the cellular and molecular mechanisms modulating immune response to cancer. This network was designed to significantly advance anti-cancer immunotherapeutics and accelerate discovery towards benefiting patients who may stand to gain from novel immune agents as mono therapy or in combination.
www.roche.com



The OCTC - Oncology Clinical and Translational Consortium, a collaborative scientific research network comprised of 6 renowned comprehensive cancer centers, was launched by GSK in 2013.
While GSK gains OCTC's expertise in preclinical, translational and clinical development of novel anticancer therapeutics, the participating centers have access to studies with GSK's early stage oncology pipeline and opportunities to accelerate and advance the next generation of novel oncology therapeutics.
www.gsk.com

Accreditation



In 2017 VHIO underwent evaluation for accreditation of the CERCA Institute of Research Centres of Catalunya (Institució CERCA–Centres de Recerca de Catalunya) for the period 2013–2016.
In recognition of VHIO's progress, performance in knowledge transfer activities and management of excellence, VHIO was awarded the maximum qualification of an A grading.
www.cerca.cat/en/



The European Commission’s Human Resources for Research (HRS4R) strategy enables research institutions of excellence to actively implement and uphold the requisites of The European Charter for Researchers and Code of Conduct for the Recruitment of Researchers for their HR policies and practices.
VHIO’s comprehensive analysis and action plan was officially approved by HRS4R assessors in 2018 and our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favorable work environment.
https://www.vhio.net/about-vhio/hrs4r/
Also reflective of our dedication to excellence and the quality of our services and procedures, VHIO’s Cancer Genomics and Molecular Oncology Groups are both ISO -accredited for their testing methods and technologies.



Similarly, VHIO continues to meet the high standards in quality and procedures in the audit of our clinical trials Units, carried out by the Generalitat de Catalunya. Our Research Management is also endorsed by ISO 9001 Certification.

New funding and projects in 2020


Departament de Salut: Budgetary support Departament d’Empresa i Coneixement: Budgetary support


VHIO’s CELLEX Building & Infrastructure


Advanced Molecular Diagnostics Program (DIAMAV), and other VHIO investigators, groups and projects


Research Unit for Molecular Therapy of Cancer (UITM) - CaixaResearch, and CaixaResearch Advanced Oncology Research Program


Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI)


International Support


H2020-SC1-2020-Lump-Sum-RTD – International Consortium – Ref: 965397
Building Data Rich Clinical Trials — CCE_DART
Consortium leader VHIO: Elena Garralda
Early Clinical Drug Development Group
NFRP-2019-2020– International Consortium – Ref: 899995
European Medical application and radiation protection concept: strategic research agenda and roadmap interlinking to health and digitisation aspects — EURAMED rocc-n-roll
PI VHIO: Jordi Giralt
Radiation Oncology Group
Granted to Joaquín Mateo
Prostate Cancer Translational Research Group


Interreg – POCTEFA – International Consortium* – Ref: EFA360/19
Red cooperativa franco-española para el análisis de proteinopatías y el desarrollo de terapias individualizadas en cánceres hematológicos (Proteoblood)
PI VHIO: David Valcarcel
Experimental Hematology Group


Clinical Unit Visit
Granted to Herminia Fernandes
Mentor: Teresa Macarulla
Gastrointestinal & Endocrine Tumors Group
Clinical Unit VisitTranslational/Clinical Research Fellowship
Impact of microbiota on breast cancer prognosis and treatment efficacy
Granted to Andri Papakonstantinou
Mentor: Mafalda Oliveira
Breast Cancer & Melanoma Group


Breast Cancer Research Foundation Grant
Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system
PI: Joaquín Arribas
Growth Factors Group


National Funding


Ajuts Producte destinats a l’obtenció de prototipus i a la valorització i transferència dels resultats d’investigació generada per equips de recerca de Catalunya* – Ref: 2019PROD00045
PARPiPRED, test diagnòstic que facilita la medicina personalitzada en el tractament del cáncer
PI VHIO: Violeta Serra
Experimental Therapeutics Group
Ajuts per a projectes de valorització i transferència de coneixement desenvolupats per innovadors en estades en entitats del sistema de recerca i innovació de Catalunya* – Ref: 2019 INNOV 00028
ONIRIA: Mastering Cell Dormancy to Fight Cancer
Granted to Teresa Tarragó
Project Director: Héctor G. Palmer
Stem Cells & Cancer Group
Ajuts per a la incorporació de personal investigador postdoctoral al sistema català de ciència i tecnologia dins del programa Beatriu de Pinós – Ref: 2019 BP 00182
Improving patient Selection for immunotherapy: Multi-Omics signature of Response Evaluation (ISeeMORE)
Granted to Kinga Bernatowicz
Project Director: Raquel Perez-Lopez
Radiomics Group
Co-funded by H2020 Programme under Marie Sklodowska-Curie COFUND Grant Agreement (BP3, Ref: 801370)
Ajuts per a la contractació de personal investigador novell – FI Predoctoral – Ref: 2020 FI_B 00584
Functional impact assessment of variants of unknown clinical significance of hereditary breast and ovarian cancer predisposition genes
Granted to Joanna Domenech
Project Director: Sara Gutierrez Enríquez
Hereditary Cancer Genetics Group
Ajuts per a la contractació de personal investigador novell – FI Predoctoral – Ref: 2020 FI_B 00774
Redirection of T cells against HER2-driven tumors
Granted to Macarena Román
Project Director: Joaquín Arribas
Growth Factors Group


DEPARTAMENT DE SALUT
Projectes de recerca i innovació per a la prevenció i tractament de la malaltia Covid-19 – Ref: SLD019/20/00001
MSC1, an anti-LIF therapeutic antibody, as a potential treatment for CoVid19
PI: Joan Seoane
Gene Expression & Cancer Group
PREMI ICS TRAJECTORIA INVESTIGADORA
Josep Tabernero
Gastrointestinal & Endocrine Tumors Group


Proyectos I+D+i Retos de Investigación. Categoria JIN – Ref: PID2019-108008RJ-I00
Proteínas de fusión BRD-NUT en el carcinoma de línea media NUT: del diagnóstico al tratamiento
PI: Tian Tian
Chromatin Dynamics in Cancer Group
Proyectos I+D+i Retos Colaboración – Ref: RTC2019-007067-1
Estrategias para incrementar el potencial clínico de inhibidores de MYC: identificación de biomarcadores, sinergias y nuevas indicaciones
PI: Laura Soucek
Mouse Models of Cancer Therapies Group
Europa Redes y Gestores – Ref: ECT2020-000827
Creación de VHIOSfera Europa: área pionera en la dinamización de Propuestas Internacionales Competitivas en Oncología de Precisión
PI: Alejandro Piris
Ayudas para Contratos Ramon y Cajal – Ref: RYC2019-026576-I
Granted to Jose Antonio Seoane
Ayudas Contratos Juan de la Cierva Formación – Ref: FJC2019-041005-I
Granted to Lidia Mateo
Project Director: Joan Seoane
Gene Expression & Cancer Group
Ayudas Contratos Juan de la Cierva Formación – Ref: FJC2019-039770-I
Granted to Alberto Gonzalez-Medina
Project Director: Ana Vivancos
Cancer Genomics Group
Ayudas contratos Predoctorales para la formación de doctores FPI – Ref: PRE2019-088051
Granted to Alba Escriche
Project Director: Maria Abad
Cellular Plasticity & Cancer Group


FINANCIACIÓN EXTRAORDINARIA DE PROYECTOS DE INVESTIGACIÓN SOBRE EL SARS-COV-2 Y LA ENFERMEDAD COVID-19 – Ref: COV20/00324
Functional characterization of SARS-CoV-2 T and B cell long-lasting Immunity in immunosuppressed patients developing SARS-CoV-2 infection (COV-Immunity)

Granted to Oriol Bestard (IDIBELL)
PI VHIO subcontracted: Alena Gros
Tumor Immunology & Immunotherapy Group


VHIO projects managed through the Instituto de Investigación Sanitaria Acreditdo Institut de Recerca (Accredited Research Institute - Vall d'Hebron)


Proyectos de Investigación Clínica Independiente – Ref: ICI20/00076
Next generation TIL therapy targeting neoantigens for immune checkpoint blockade-resistant tumors*
PI: Elena Garralda
Early Clinical Drug Development Group
Proyectos de Investigación en Salud – Ref: PI20/00892
Developing new therapeutic strategies to overcome CDK4/6 resistance in oestrogen receptor positive breast cancer*
PI: Violeta Serra/Meritxell Bellet
Experimental Therapeutics Group
Proyectos de Investigación en Salud – PI20/00897
Targeting dormant tumor cells as a new strategy to fight cancer*
PI: Héctor G. Palmer
Stem Cells & Cancer Group
Proyectos de Investigación en Salud – PI20/00968
Identification and validation of sensitivity signatures and mechanisms of resistance and response to targeted therapies and immunotherapy in patients with advanced colorectal cancer*
PI: Josep Tabernero/Elena Élez
Gastrointestinal & Endocrine Tumors Group
Proyectos de Investigación en Salud – PI20/00987
Chromosome instability and tumor immune infiltration as determinants of lung cancer metastatic potential*
PI: Enriqueta Felip
Thoracic Tumors & Head and Neck Cancer Group
Proyectos de Investigación en Salud – PI20/01274
Deciphering the mechanisms of response and clonal evolution in high-risk chronic lymphocyticleukemia treated with highly specific BTK inhibitors*
PI: Francesc Bosch
Experimental Hematology Group
Proyectos de Investigación en Salud – PI20/00898
Pancreatic cancer and alterations in DNA damage response genes: analysis of predictive biomarkers and mechanisms of resistance to platinum-based chemotherapy and PARP inhibitors*
PI: Teresa Macarulla
Gastrointestinal & Endocrine Tumors Group
Proyectos de Investigación en Salud – PI20/00895
Investigating the mechanisms of resistance to RET-inhibitors in endocrine tumors*
PI: Jaume Capdevila
Gastrointestinal & Endocrine Tumors Group
Proyectos de Investigación en Salud – PI20/00881
Clonal Hematopoiesis of Indeterminate Potential in Cancer Patients: Impact on Immune Dysfunction, Treatment Response and Therapy Related Malignancies
PI: David Valcarcel*
Experimental Hematology Group
Proyectos de Investigación en Salud – PI20/00889
FUSOMAP: Development of microbiota-based diagnostic and prognostic models by mapping intratumoral Fusobacterium and associated gut microbiota in early-stage colorectal cancer*
PI: Paolo Giovanni Nuciforo
Molecular Oncology Group
Proyectos de Investigación en Salud – PI20/01112
Moving liquid biopsy toward clinical implementation: Study of the molecular origin of cell-free tumor DNA release into the bloodstream*
PI: Ana Vivancos
Cancer Genomics Group
Proyectos de Investigación en Salud* – PI20/00558
Exploiting senescence in a two-step approach to treat advanced Prostate Cancer*
PI: Nicolás Herranz
Prostate Cancer Translational Research Group
Contratos Miguel SERVET Tipo II* – CPII20/00020
Granted to Alena Gros
Tumor Immunology & Immunotherapy Group
Ayudas para la Intensificación de la Actividad Investigadora* – INT20/00042
Granted to Judith Balmaña
Hereditary Cancer Genetics Group
Ayudas para Contratos Predoctorales de Formación en Investigación en Salud* – FI20/00188
Granted to Alejandro Martínez-Sabadell
Project Director: Joaquín Arribas
Growth Factors Group
Ayudas para Contratos Predoctorales de Formación en Investigación en Salud* – FI20/00274
Granted to Fabio Giuntini
Project Director: Laura Soucek
Mouse Models of Cancer Therapies Group
Ayudas para Contratos Predoctorales de Formación en Investigación en Salud* – IMP/00009
Granted to David Gomez Peregrina
Project Director: César Serrano
Sarcoma Translational Research Group
IMPaCT* – FI20/00275
Medicina Genómica


Convocatoria para Adjudicación de Ayudas para Proyectos de Investigación en Salud Desarrollo de modelos diagnósticos y pronósticos basados en la infección intratumoral por Fusobacterium y microbiota intestinal asociada en el cáncer colorectal localizado, en el área de Oncologia
PI: Paolo Giovanni Nuciforo
Molecular Oncology Group


Ayudas Predoctorales InPhinit Incoming
Granted to Judit Diaz
Project Director: Alena Gros
Tumor Immunology & Immunotherapy Group


Private Funding


CaixaImpulse Consolidate
PI: Violeta Serra
Experimental Therapeutics Group
Caixa Health Research Grant - NATIONAL CONSORTIUM
BioPrinted hydROgel MicrofluIdicS to mimic patient-specific tumor metastasic micrenvironment-PROMISE
PI VHIO: Elena Élez
Gastrointestinal & Endocrine Tumors Group  Junior Leader Incoming
Granted to Irene Casanova
Project Director: Joaquín Mateo
Prostate Cancer Translational Research Group
Co-funded by H2020 Programme under Marie Sklodowska-Curie Grant Agreement (Ref: 801370)
Ayudas Predoctorales InPhinit Retaining
Granted to Alex Mur
Mentor: Héctor G. Palmer
Stem Cells & Cancer Group


Beca FERO en Investigación Oncológica Traslacional
Unraveling the tumor immunotherapy with deep-learning based radiogenomics
PI: Raquel Perez-Lopez
Radiomics Group
Proyectos FERO-GHD en Cáncer de Mama
ctDNA in breast milk for early detection of pregnancy associated breast cancer
PI: Cristina Saura/Miriam Sansó
Breast Cancer & Melanoma Group
Estudios biofísicos y bio-informáticos de los complejos proteicos HER2-Pertuzumab en presencia del Trastuzumab innovador vs biosimilar
PI: Javier Cortés
Breast Cancer & Melanoma Group
TNBC Tumores inmunológicamente inflamados
PI: Javier Cortés
Breast Cancer & Melanoma Group
Análisis de las imágenes de Tomografía Computarizada (TAC) para identificar susceptibles de responder a inmunoterapia
PI: Raquel Perez-Lopez
Radiomics Group


Grupos Coordinados AECC- NATIONAL CONSORTIUM
Tumor microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications
PI VHIO: Héctor G. Palmer
Stem Cells & Cancer Group
LAB AECC
Leveraging the AR-DDR interaction in de-novo metastatic prostate cancer towards precision combination therapies with PARP inhibitors.
PI: Joaquin Mateo
Prostate Cancer Translational Research Group
INNOVA AECC
First-in-class small drug activators of TET2 for the treatment of cancer
PI: Héctor G. Palmer
Stem Cells & Cancer Group
Ideas Semilla
Dormancy and autophagy: decoding the molecular mechanism that mediates cancer drug resistance
PI: Isabel Puig
Stem Cells & Cancer Group
Clínico Senior AECC
Molecular landscape of resistance to KIT/PDGFRA inhibition in gastrointestinal stromal tumors
Granted to César Serrano
Project Director Joan Carles Galcerán
Genitourinary, CNS & Sarcoma Tumors Group
Investigador AECC
Characterisation of fusion protein BRD-NUT in NUT midline carcinoma: from diagnosis to treatment
Granted to Tian Tian
Project Director Sandra Peiró
Chromatin Dynamics in Cancer Group
Investigador AECC
Tumor DNA repair functionality and immunologic profile as predictive and prognostic biomarkers for cancer precision medicine
Granted to Alba Llop
Project Director Violeta Serra
Experimental Therapeutics Group
Postdoc AECC
Study of the impact of LIF and the tumor microenvironment on the immunomodulation of brain metastasis
Granted to Ester Bonfill
Project Director Joan Seoane
Gene Expression & Cancer Group


Programa Joves i Ciència. Premio Pedrera Talents
Granted to Iosune Baraibar
Co-Mentors: Joan Seoane and Elena Élez
Gastrointestinal & Endocrine Tumors Group and Gene Expression and Cancer Group


Beca SEOM para Proyectos de Investigación de Oncología Médica relacionados con Medicina Nuclear
Desarrollo de un sistema de cuantificación volumétrica de carga tumoral mediante estudios con PET 68Ga-DOTATOC con valor pronóstico y predictivo de respuesta a 177Lu-DOTATATE en pacientes con tumores neuroendocrinos gastroenteropancreáticos
PI: Jaume Capdevila
Gastrointestinal & Endocrine Tumors Group


Fundación CRIS. Programa CRIS Talento Clínico Personalized REsponse Imaging biomarker for Cancer immunotherapy PI: Raquel Perez-Lopez Radiomics Group


BECA GETNE Estudio de la microbiota, de Fusobacterium Nucleatum y de la correlación con las vías de los receptores de TOLL-LIKE en tumores neuroendocrinos de intestino delgado PI: Jaume Capdevila Gastrointestinal & Endocrine Tumors Group


Premio Chiara Giorgetti
Identificación de pacientes con cáncer de mama metastásico sensibles a los inhibidores de PARP: estudio en pacientes con variantes hereditarias de significado incierto y en nuevos genes implicados en la recombinación homóloga
PI: Judith Balmaña
Hereditary Cancer Genetics Group


Vyda GEIS
DIVAS-DIssecting VAsculas Sarcomas
PI: Claudia Valverde
Genitourinary, CNS & Sarcoma Tumors Group